Sign In
Last checked at 
22 Sep 2025 16:45
Haleon plc: Director/PDMR Shareholding
22 September 2025: Haleon plc (the "Company" or "Haleon") (LSE/NYSE:HLN) today announces notification and public disclosure in accordance with the requirements of The UK Market Abuse Regulation of Transactions by Persons Discharging Managerial Responsibilities ("PDMRs").
On 19 September 2025, the Company received notification of the following transactions as detailed below.
1
| Details of the person discharging managerial responsibilities / person closely associated
| |||||
a)
| Name
| Tamara Rogers | ||||
2
| Reason for the notification
| |||||
a)
| Position/status
| Chief Marketing Officer - PDMR | ||||
b)
| Initial notification /Amendment | Initial Notification | ||||
3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a)
| Name
| Haleon plc | ||||
b)
| LEI
| 549300PSB3WWEODCUP19 | ||||
4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a)
| Description of the financial instrument, type of instrument | Ordinary Shares of £0.01 each | ||||
Identification code | GB00BMX86B70 | |||||
b)
| Nature of the transaction
| Acquisition of Ordinary Shares in respect of dividend reinvestment.
| ||||
c)
| Price(s) and volume(s) | |||||
Price(s) | Volume(s) | |||||
£3.441 | 5 | |||||
d)
| Aggregated information | |||||
- Aggregated volume | N/A | |||||
- Price | ||||||
e)
| Date of the transaction
| 18 September 2025 | ||||
f)
| Place of the transaction
| London Stock Exchange (XLON) | ||||
1
| Details of the person discharging managerial responsibilities / person closely associated
| ||||
a)
| Name
| Alan Stewart | |||
2
| Reason for the notification
| ||||
a)
| Position/status
| Independent Non-Executive Director - PDMR | |||
b)
| Initial notification /Amendment
| Initial Notification | |||
3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| ||||
a)
| Name
| Haleon plc | |||
b)
| LEI
| 549300PSB3WWEODCUP19 | |||
4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| ||||
a)
| Description of the financial instrument, type of instrument
Identification code
| Ordinary Shares of £0.01 each
GB00BMX86B70
| |||
b)
| Nature of the transaction
| Acquisition of Ordinary Shares as a result of dividend reinvestment
| |||
c)
| Price(s) and volume(s) | ||||
Price(s) | Volume(s) | ||||
£3.424442 | 214 | ||||
d)
| Aggregated information | ||||
- Aggregated volume | N/A | ||||
- Price | |||||
e)
| Date of the transaction
| 18 September 2025
| |||
f)
| Place of the transaction
| London Stock Exchange (XLON) | |||
Amanda Mellor
Company Secretary
About Haleon
Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are built on trusted science, innovation and deep human understanding.
For more information, please visit www.haleon.com.
Follow the stocks
